Drug Profile
Research programme: histamine H4 receptor antagonists - Cellzome
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cellzome
- Developer GSK
- Class Small molecules
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in Germany
- 21 May 2012 Cellzome has been acquired and merged into GlaxoSmithKline
- 11 Oct 2007 Preclinical trials in Allergic rhinitis in Germany (unspecified route)